LGVN

Longeveron

0.8561 USD
-0.0067
0.78%
At close Updated May 5, 4:00 PM EDT
1 day
-0.78%
5 days
-4.82%
1 month
-22.17%
3 months
67.53%
6 months
12.35%
Year to date
44.37%
1 year
-42.93%
5 years
-98.55%
10 years
-98.84%
 

About: Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.

Employees: 38

0
Funds holding %
of 8,129 funds
Analysts bullish %
Positive news %
Price charts implemented using Lightweight Charts™